NasdaqGS - Delayed Quote • USD
Syndax Pharmaceuticals, Inc. (SNDX)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 4:04 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 11 | 11 |
| Avg. Estimate | -0.99 | -1.04 | -3.86 | -2.9 |
| Low Estimate | -1.11 | -1.21 | -4.85 | -3.74 |
| High Estimate | -0.91 | -0.95 | -3.24 | -1.06 |
| Year Ago EPS | -0.59 | -0.64 | -2.98 | -3.86 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 11 | 11 |
| Avg. Estimate | -- | -- | 29.47M | 129.01M |
| Low Estimate | -- | -- | 5.98M | 71.05M |
| High Estimate | -- | -- | 81M | 278.08M |
| Year Ago Sales | -- | -- | -- | 29.47M |
| Sales Growth (year/est) | -- | -- | -- | 337.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.6 | -0.73 | -0.79 | -0.99 |
| EPS Actual | -0.59 | -0.64 | -0.73 | -1 |
| Difference | 0.01 | 0.09 | 0.06 | -0.01 |
| Surprise % | 1.70% | 12.30% | 7.60% | -1.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.99 | -1.04 | -3.86 | -2.9 |
| 7 Days Ago | -0.99 | -1.04 | -3.86 | -2.9 |
| 30 Days Ago | -0.99 | -1.04 | -3.87 | -2.89 |
| 60 Days Ago | -0.85 | -0.88 | -3.18 | -2.43 |
| 90 Days Ago | -0.85 | -0.88 | -3.19 | -2.43 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SNDX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -67.80% | -- | -- | 1.60% |
| Next Qtr. | -62.50% | -- | -- | 10.50% |
| Current Year | -29.50% | -- | -- | 5.20% |
| Next Year | 24.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/28/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/27/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 3/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/28/2024 |
| Downgrade | Scotiabank: Sector Outperform to Sector Perform | 1/31/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/2/2024 |
Related Tickers
MRUS Merus N.V.
39.81
-1.63%
CRNX Crinetics Pharmaceuticals, Inc.
42.97
-0.09%
KURA Kura Oncology, Inc.
17.53
-0.85%
SWTX SpringWorks Therapeutics, Inc.
40.10
-5.58%
IMCR Immunocore Holdings plc
55.68
+1.72%
XENE Xenon Pharmaceuticals Inc.
39.88
-1.07%
CABA Cabaletta Bio, Inc.
13.34
-4.51%
REPL Replimune Group, Inc.
6.45
-7.46%
SRRK Scholar Rock Holding Corporation
13.85
-0.72%
EWTX Edgewise Therapeutics, Inc.
15.23
-1.42%